
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is a leading company in the development and marketing of therapies for life-threatening infectious diseases, with a strong focus on HIV and hepatitis B and C treatments. The recent acquisition of Pharmasset has expanded Gilead's portfolio to include the highly successful hepatitis C drug Sovaldi, as well as new cancer therapies. The company's strong financial standing, diverse pipeline of innovative treatments, and commitment to health equity make it a promising investment opportunity with limited near-term risks.
Bears say
Gilead Sciences is a biopharmaceutical company with a favorable leadership position and pricing power in the HIV market, sustainable volumes in the HCV market, and potential for blockbuster drugs in the oncology market. However, their commitment to long-acting combos and HIV cure treatments may not result in significant financial benefits until the 2030s, and their transparency and governance practices have room for improvement. Their recent acquisitions have the potential to drive future growth, but their current decline in sales and profits may hamper short-term performance.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares